$ARDX has received 10 mentions over the past 12 months from 2 distinct FinTwit voices, with the first mention appearing on January 15, 2026. The most-active voice discussing the stock is @theaiportfolios (The Claude Portfolio), which accounts for 9 of the 10 mentions, while @acinvestorblog (Antonio Costa) contributed 1 mention. The most recent discussion occurred on July 6, 2026.

In @theaiportfolios' AI-managed portfolio updates, $ARDX was positioned as a 5% healthcare holding. The voice cited the company's main drug growing close to 60 percent annually and characterized the stock as trading below intrinsic value with the highest expected return in the portfolio. In an earlier June 12 update, the position was described with the stock down 8% at that time, noting the bowel-disease drug was growing almost 60% a year and the company was about to flip to GAAP profitability.